Key result
CRT-D showed no significant difference in 180-day heart failure readmissions compared with CRT-P in patients with nonischemic cardiomyopathy.
Why the study?
Recent real-world data comparing the relative effectiveness of CRT-D and CRT-P in patients with nonischemic cardiomyopathy were lacking.
Does cardiac resynchronization therapy with defibrillator (CRT-D) reduce 180-day heart failure readmissions, all-cause readmissions, or all-cause mortality compared to CRT with pacing alone (CRT-P) in patients with nonischemic cardiomyopathy?
Cohort (n=12,200)
Yes
Does cardiac resynchronization therapy with defibrillator (CRT-D) reduce 180-day heart failure readmissions, all-cause readmissions, or all-cause mortality compared to CRT with pacing alone (CRT-P) in patients with nonischemic cardiomyopathy?
In a large real-world US cohort of patients with nonischemic cardiomyopathy receiving CRT, adding a defibrillator (CRT-D) was not associated with significant reductions in 180-day heart failure readmissions, all-cause readmissions, or all-cause mortality compared to CRT-P alone.
Answers are grounded in this paper and cite their sources.
CRT-D should not yet change device selection over CRT-P; leaves open whether RCTs will show benefit in nonischemic cardiomyopathy.
INTRODUCTION: Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real- world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit. METHODS: We searched the National Readmissions Database (NRD) from 2016-2020 to identify hospitalizations with NICM using appropriate ICD-10 diagnosis and procedure codes. The cohort was further divided into groups with NICM and CRT-D implantation and NICM with CRTP implantation. RESULTS AND DISCUSSION: Our final cohort included 8,801 hospitalizations with NICM and CRTD implantation and 3,399 hospitalizations with NICM and CRT-P implantation. Propensity matching was performed using comorbidities through multivariate logistic regression. Two thousand nine hundred seventeen hospitalizations were included in each of the two groups, CRT-D and CRT-P. Analysis of the propensity-matched cohorts at 180 days revealed a trend toward lower heart failure readmission, all-cause readmission, and all-cause mortality rates in the group with CRT-P implantation. However, there was no difference noted in the 180-day hazard ratios of HF readmission [1.08 (0.98-1.19); p = 0.1], all-cause readmission [1.04 (0.87- 1.12); p = 0.23], and all-cause mortality [0.83 (0.58-1.19); p = 0.32]. CONCLUSION: It was found that NICM patients with CRT-D have a trend towards higher HF readmissions, all-cause readmission, and all-cause mortality compared to those with CRT-P, but no significant difference was noted in hazard ratios. The findings of our study raise further questions about the need for defibrillator therapy in patients with NICM and merit further studies to better select candidates for each of these therapies.
No takes yet. Share an insight, caveat, or question.
Sheth et al. (2025) conducted a cohort in Nonischemic cardiomyopathy (NICM) with heart failure with reduced ejection fraction undergoing CRT implantation (n=12,200). Cardiac resynchronization therapy with pacing and defibrillator (CRT-D) vs. Cardiac resynchronization therapy with pacing alone (CRT-P) was evaluated on Heart failure readmission at 180 days (propensity-matched cohort) (HR 1.08, 95% CI 0.98-1.19, p=0.1). CRT-D showed no significant difference in 180-day heart failure readmissions compared with CRT-P in patients with nonischemic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: